Sulfonylureas increase the incidence of severe hypoglycemia in people with type 2 diabetes and might increase the risk of sudden cardiac death. Sulfonylureas stimulate insulin secretion by closing pancreatic ATP-sensitive potassium ion (K ATP ) channels. To investigate the role of K ATP channel modulators on cardiac arrhythmias and mortality in the setting of severe hypoglycemia, adult Sprague-Dawley rats underwent hyperinsulinemic (0.2 U/kg/min) severe hypoglycemic (10 to 15 mg/ dL) clamps with continuous electrocardiography. The rats were randomized for treatment with intravenous vehicle (VEH), the sulfonylurea glibenclamide (GLIB; K ATP channel blocker; 5 mg/kg/h), or diazoxide (DIAZ; K ATP channel opener; 5 mg/kg/h). The results demonstrated that GLIB completely prevented first-degree heart block compared with VEH (0.18 6 0.09/min) and DIAZ (0.2 6 0.05/min). Second-degree heart block was significantly reduced with GLIB (0.12 6 0.1/min) compared with VEH (0.6 6 0.2/min) and DIAZ (6.9 6 3/min). The incidence of third-degree heart block was completely prevented by GLIB compared with VEH (67%) and DIAZ (87.5%). Hypoglycemiainduced mortality was completely prevented by GLIB compared with VEH (60%) and DIAZ (82%). In conclusion, although GLIB increases the risk of hypoglycemia by increasing insulin secretion, these results have demonstrated a paradoxical protective role of GLIB against severe hypoglycemiainduced fatal cardiac arrhythmias. (Endocrinology 159: 2614(Endocrinology 159: -2620(Endocrinology 159: , 2018 
S everal large clinical trials found that intensive glycemic control in people with type 2 diabetes is associated with an increased incidence of severe hypoglycemia (1) (2) (3) . Although it was difficult to identify hypoglycemia as a cause of death in these studies, intensive glucose control has been shown to be associated with both severe hypoglycemia and increased mortality (4, 5) . Thus, similar to studies of people with type 1 diabetes, tight glucose control has been shown to increase the risk of hypoglycemia and death in people with type 2 diabetes (3, 6, 7) . Although the cause of death was not always identified, patients with type 2 diabetes and a history of cardiovascular disease are highly susceptible to nocturnal hypoglycemia-induced cardiac arrhythmias (7) . Of particular note, in a previous report, severe hypoglycemia was associated with a significant 1.77-fold increased risk of arrhythmic death (3) . Demonstrating a link between severe hypoglycemia and sudden death, our laboratory previously reported that severe hypoglycemia-induced sudden death can be attributed to fatal cardiac arrhythmias (8) ; however, the mechanisms of how severe hypoglycemia leads to fatal cardiac arrhythmias remain poorly understood.
Based on side effects, including weight gain and severe hypoglycemia, recent clinical recommendations have tended to recommend against sulfonylurea usage in favor of other oral antihyperglycemic agents (9) . However, based on their low cost, efficacy, tolerability, and physician experience, sulfonylureas remain the most common second-line therapy for treatment of type 2 diabetes (10) . Sulfonylureas act to increase insulin secretion via blocking ATP-sensitive potassium channels (K ATP ) on pancreatic b-cells. However, because sulfonylureas also modulate K ATP channels in the heart, these drugs might play an important role in mediating cardiac arrhythmias (11, 12) . Studies have indicated sulfonylurea treatment is associated with an increased incidence of cardiovascular death (13, 14) . In contrast, K ATP channel opening has been thought to protect against ischemic injuries (15) . Taken together, it is important to understand how sulfonylureas (and, thus, K ATP function) might affect hypoglycemia-induced cardiac arrhythmias. To mechanistically test how drugs that alter K ATP channels might regulate cardiac arrhythmias induced by hypoglycemia, K ATP channel blockers [i.e., the sulfonylurea glibenclamide (GLIB)] or K ATP channel openers [diazoxide (DIAZ)] were infused into rats during hypoglycemia, and the incidence of cardiac arrhythmias was evaluated. By understanding how cardiac K ATP channels might regulate hypoglycemia-induced cardiac arrhythmias, better treatment strategies for those with diabetes can be developed to help reduce the risk of hypoglycemia-induced sudden death.
Materials and Methods

Animals
Adult, male Sprague-Dawley rats (weight, 250 to 300 g; Charles River Laboratories, Worcester, MA) were housed individually in temperature-and light-controlled (12 hours on and 12 hours off) environment and fed ad libitum with standard rat chow diet and water. All studies were performed in accordance with, and approved by, the animal studies committee at the University of Utah School of Medicine.
Surgery
The rats underwent surgery for carotid artery and jugular vein and electrocardiographic (ECG) lead placement 1 week before the clamp, as previously described (8) .
Hyperinsulinemic-hypoglycemic clamp
Awake, unrestrained, overnight-fasted rats underwent a hyperinsulinemic (0.2 U/kg/min; Humulin R) severe hypoglycemic (10 to 15 mg/dL) clamp for 3 hours. Severe hypoglycemia in rats is defined in our laboratory as 10 to 15 mg/dL. This degree of hypoglycemia reliably results in coma, seizures, and cardiac arrhythmias (8) . The rats were divided into three groups: group 1, vehicle (VEH; 17.5% ethanol/NaOH in water; n = 10); group 2, GLIB (5 mg/kg/h; Sigma-Aldrich, St. Louis, MO; n = 7); and group 3, DIAZ (5 mg/kg/h; Sigma-Aldrich; n = 11). Both GLIB and DIAZ were separately dissolved in the VEH solution. Each drug was infused intravenously starting 15 minutes before the insulin infusion and continued throughout the clamp. Continuous ECG monitoring was performed throughout the clamp using PowerLab 26T (LabChart; ADInstruments, Colorado Springs, CO). QTc (corrected QT interval; representative of ventricle depolarization and repolarization) was calculated using Bazett formula. Respiration was measured and recorded by counting the visible breaths. Visible seizure-like activity (i.e., twitch, rolling) was quantified.
Hormone samples
Blood samples were taken through an arterial cannula during the hyperinsulinemic-severe hypoglycemic clamp to measure catecholamines (ELISA; Abnova, Taipei, Taiwan), insulin (ELISA; Crystal Chem, Elk Grove Village, IL), and blood glucose levels (Ascensia Contour BG monitors; Bayer Healthcare, Mishawaka, IN).
Statistical analysis
All data are presented as the mean 6 SE. ANOVA was used to determine the significance among the three groups when comparing the mean glucose levels, glucose infusion rates, hormones, and occurrence of arrhythmias. The Tukey test was used for post hoc analysis of multiple comparisons. A repeated measures ANOVA was used to determine the significance for the glucose infusion rates over time and among the groups. The Fisher exact test with FreemanHalton extension was used to compare mortality and the incidence of arrhythmias. Significance was determined at P , 0.05.
Results
The glucose levels were evenly matched during the hyperinsulinemic, severe hypoglycemic clamp (VEH, 11.8 6 0.4 mg/dL; GLIB, 10.9 6 0.5 mg/dL; DIAZ, 10.8 6 0.3 mg/dL; Fig. 1A ). The GLIB group had a fivefold higher glucose infusion rate (3 6 0.3 mg/kg/min) compared with the VEH group (0.6 6 0.18 mg/kg/min); the infusion rate of the DIAZ group (1.1 6 0.13 mg/kg/ min) was not different from that of the VEH group (Fig. 1B) . The increased glucose infusion rate in the GLIB group was associated with a blunted epinephrine response (3751 6 210 pg/mL; P , 0.02) during severe hypoglycemia compared with the VEH group (6024 6 585 pg/mL; Fig. 1C ). The DIAZ group had an epinephrine response during severe hypoglycemia (8902 6 2389 pg/mL) similar to that of the VEH group. Norepinephrine increased during severe hypoglycemia compared with basal but to a similar extent in all three groups (Fig. 1D) .
The plasma insulin level was similar in all three groups at baseline (before the drug infusion). Fifteen minutes after starting the drug infusions, the GLIB-treated rats tended to have higher insulin values but this did not reach significance (Fig. 1E ). By design, the plasma insulin was similar among the three groups during the hyperinsulinemic hypoglycemic clamp.
Mortality during severe hypoglycemia was completely prevented in the GLIB group (P , 0.005; Fisher exact test, Freeman-Halton extension). In contrast, mortality with DIAZ (82%) was not different from that with VEH (60%; Fig. 2A ). Prevention of mortality in the GLIB group was associated with a decreased incidence of many different cardiac arrhythmias (Fig. 2B-2F ). First-degree heart block was prevented by GLIB. In contrast, VEH resulted in a frequency of 0.18 6 0.07/min and DIAZ in 0.4 6 0.14/min (Fig. 2B) . Second-degree heart block was decreased 5.1-fold in the GLIB group (0.12 6 0.1/min), a significant difference, and increased 3-fold in the DIAZ group (1.9 6 0.8/min) compared with the VEH group (0.6 6 0.2/min; P , 0.05, ANOVA). Third-degree heart block was completely prevented by GLIB (P , 0.008, Fisher exact test, Freeman-Halton extension). In contrast, DIAZ (87.5%) had an incidence of third-degree heart block similar to that with VEH (67%; Fig. 2D ). The incidence of premature ventricular contractions was not different among the three groups (Fig. 2E) . Although the incidence of nonsustained ventricular tachycardia (four or more consecutive premature ventricular contractions) was prevented in the GLIB group, no significant differences were found among the groups (VEH, 56%; GLIB, 0%; DIAZ, 29%; Fig. 2F ). Immediately preceding respiratory arrest, the ECG tracings showed second-and third-degree heart block in the VEH and DIAZ groups. However, the GLIB group had a relatively normal heart beat after 3 hours of severe hypoglycemia (Fig. 3) .
During the first 15 minutes of the drug infusion (i.e., before insulin infusion), the heart rate remained similar in the VEH and GLIB groups, although the DIAZ group had an increased heart rate [from 393 6 4 beats per minutes (bpm) in the basal period to 417 6 5 bpm after DIAZ infusion; P , 0.001, t test). Compared with their respective basal values, the heart rate decreased during severe hypoglycemia in all three groups (Fig. 4A) . The mean heart rate during severe hypoglycemia was similar between the VEH (292 6 8 bpm) and GLIB (273 6 11 bpm) groups but was higher in the DIAZ group (317 6 9 bpm; P , 0.05, ANOVA; Fig. 4A ) despite the increased heart block.
The QTc increased during severe hypoglycemia from basal in all three groups (Fig. 4B) . During severe hypoglycemia, the mean QTc was increased in the DIAZ group (204 6 5 ms; P , 0.01, ANOVA) compared with the VEH group (186 6 5 ms), and the mean QTc in the GLIB group (194 6 9 ms) was similar to that for the VEH group (Fig. 4B) .
Respiration was similar among the groups during severe hypoglycemia (VEH, 69 6 5 breaths/min; GLIB, 62 6 4 breaths/min; DIAZ, 60 6 3 breaths/min; Fig. 4C ). The incidence of seizures was also similar among the three groups (Fig. 4D) .
Discussion
To determine the role of K ATP channels in mediating arrhythmias during severe hypoglycemia, the drugs GLIB and DIAZ were used to close and open the K ATP channels, respectively. Surprisingly, and in contrast to our The glucose infusion rate to maintain hypoglycemia was significantly increased at time points during severe hypoglycemia in GLIB (*P , 0.05 vs VEH; repeated measures ANOVA). DIAZ had a similar glucose infusion rate compared with VEH (n = 7 to 11 per group). (C) Compared with basal, epinephrine increased in all groups during severe hypoglycemia. However, this epinephrine response was blunted in the GLIB group compared with the VEH group ( # P , 0.02; ANOVA): VEH (closed circles, white bars), GLIB (closed squares, gray bars), DIAZ (closed triangles, diagonal slash bars; n = 5 to 7 per group). (D) Norepinephrine was increased in all groups to a similar extent during severe hypoglycemia compared with basal: VEH (closed circles, white bars), GLIB (closed squares, gray bars), DIAZ (closed triangles, diagonal slash bars; n = 5 to 7 per group). (E) Basal (before drug infusion) insulin was similar among the three groups. After 15 minutes of VEH, GLIB, or DIAZ infusion, the insulin levels remained similar among the three groups. By design, during the hyperinsulinemic clamp, all insulin levels were similar: VEH (closed circles, white bars), GLIB (closed squares, gray bars), DIAZ (closed triangles, diagonal slash bars; n = 5 to 8 per group). Data presented as mean 6 SEM. Ginf, glucose infusion.
initial hypothesis, GLIB completely prevented sudden death and prevented nearly all types of cardiac arrhythmias during severe hypoglycemia and DIAZ increased some arrhythmias but did not significantly increase mortality. Thus, in this model, acute pharmaceutical closure of the K ATP channels with GLIB protected against fatal cardiac arrhythmias during severe hypoglycemia.
Although K ATP channel activity was not directly assessed in the present study, the data provide indirect assessments of K ATP channel activity. Specifically, in the basal period, under euglycemic conditions when the cellular ATP/ADP ratio would be expected to be normal, the data suggest that the K ATP channels within the heart are closed. First, GLIB treatment did not alter the heart rate of these rats, suggesting that the K ATP channels are Figure 3 . Representative ECG tracings. During severe hypoglycemia, the VEH and DIAZ groups experienced multiple second-degree heart block, which ultimately led to third-degree heart block just before death. For the GLIB group, the ECG tracings are shown after 3 hours of severe hypoglycemia. Although some sinus arrhythmia was present, the incidence of second-degree heart block was significantly reduced, and thirddegree heart block was prevented. constitutively closed, a finding consistent with those from other studies (16) . However, GLIB did increase the insulin levels before the clamp, indicating drug action. Second, and consistent with reported studies (17), pharmacological K ATP opening with DIAZ treatment increased the heart rate from baseline, again suggesting that under basal conditions, the K ATP channels are constitutively closed. DIAZ did not lower the insulin levels because after an overnight fast, the basal insulin was already very low.
In contrast, in the setting of hypoglycemia and low cellular ATP/ADP ratios, the presented data suggest that K ATP channels are open during hypoglycemia because treatment with the K ATP channel opener DIAZ did not have profound effects beyond that observed with VEHtreated hypoglycemic controls (i.e., the additive effect of pharmacological K ATP opening was not great). These finding are consistent with reports that cardiac K ATP channels open in response to a decrease in cellular ATP (18) . In support of this notion that the K ATP channels are open during hypoglycemia is the corollary observation that closure of these K ATP channels with GLIB had profound effects in reducing arrhythmias and increasing survival during an equivalent period of severe hypoglycemia. Taken together, the data indicate that hypoglycemia-induced opening of K ATP channels represents a key pathologic mechanism that leads to fatal arrhythmias in the setting of severe hypoglycemia.
GLIB and DIAZ can act on K ATP channels located within the ventricles, atrium, smooth muscle, and mitochondria and within the conduction system (19) . In addition to possible direct actions in the K ATP channels within the heart, these drugs might have exerted indirect effects on cardiac arrhythmias. For example, GLIB has been shown to blunt the epinephrine response to hypoglycemia when given into the brain (20) and, in contrast, DIAZ increases the epinephrine response to hypoglycemia (21) . Consistent with these reports, GLIB treatment in the present study was associated with a 38% lower epinephrine response to hypoglycemia. We could not determine whether this effect of GLIB was mediated via actions in the brain or via peripheral actions (e.g., on the adrenal medulla). Regardless of the site of action, the blunting of the epinephrine response with GLIB was associated with a markedly reduced risk of severe hypoglycemia-induced cardiac arrhythmias. These findings are consistent with our previous findings that rats with a blunted epinephrine response induced by recurrent hypoglycemic preconditioning and rats that received beta-blockers (epinephrine action blocked) were both protected against sudden death during severe hypoglycemia (8, 22 ). Thus, it is possible that rather than Figure 4 . Heart rate, QTc, respiration, and seizures during the severe hypoglycemic clamp. (A) The heart rate decreased in all groups during severe hypoglycemia compared with baseline. During severe hypoglycemia, the mean heart rate was higher in the DIAZ group (diagonal slash bars) compared with the VEH (white bars) and GLIB (gray bars) groups ( # P , 0.05, ANOVA; n = 6 to 9 per group). (B) QTc was prolonged during severe hypoglycemia in all groups compared with baseline. The mean QTc prolongation during severe hypoglycemia was increased in the DIAZ group compared with the VEH and GLIB groups ( # P , 0.01; ANOVA; n = 6 to 9 per group). (C) Respirations decreased similarly in all groups during severe hypoglycemia compared with baseline (n = 7 to 11 per group). (D) Visible seizure-like activity was similar among all three groups (n = 7 to 11 per group). Data presented as mean 6 SEM.
exerting a direct effect on the heart, GLIB might have exerted its protective effect against severe hypoglycemiainduced fatal cardiac arrhythmias via indirect mechanisms (i.e., by blunting the epinephrine response to hypoglycemia).
The beneficial effects of GLIB in nondiabetic rats observed in the present study can be viewed as somewhat paradoxical. Via their action on pancreatic b-cells, sulfonylureas cause hypoglycemia by stimulating insulin secretion. Thus, in the clinical setting, sulfonylureas increase the risk of hypoglycemia and hypoglycemiainduced arrhythmias. The results of the present study have demonstrated that sulfonylurea therapy might act to worsen the extent of hypoglycemia by blunting the counterregulatory adrenomedullary response, again increasing the risk of severe hypoglycemia. However, despite increasing the risk of hypoglycemia, the presented evidence indicates that sulfonylurea therapy might provide protection against fatal cardiac arrhythmias. Our data are supported by evidence from rat studies of heart failure in which GLIB treatment protected against ischemia-induced arrhythmias in diabetic rats hearts (12) and reduced the infarct volume in rat hearts exposed to coronary artery ligation (23) . Taken together, GLIB treatment is potentially protective against cardiac arrhythmias in multiple settings such as heart failure and hypoglycemia.
Interestingly, in all treatment groups, severe hypoglycemia was associated with both QTc prolongation and numerous hypoglycemic seizures. Given that GLIB treatment completely prevented mortality despite the QTc prolongation and occurrence of hypoglycemic seizures, the data suggest that although QTc prolongation and hypoglycemic seizures might serve as markers of severe hypoglycemia, these processes do not directly mediate hypoglycemia-associated sudden death. Also, 3 hours of severe hypoglycemia was previously shown by our laboratory to have no effect on plasma oxygen saturation, carbon dioxide, pH levels, or blood pressure (8) .
It should be emphasized that in this model, high doses of insulin were intentionally administered, because they were necessary to induce this degree of severe hypoglycemia. In the clinical situation, it would be unusual for a patient to be treated with a sulfonylurea and a high dose of a short-acting insulin (because severe hypoglycemia is never a goal). However, underscoring the clinical relevance of this situation, sulfonylurea therapy has been consistently reported to be associated with episodes of severe hypoglycemia and cardiac arrhythmias (24) (25) (26) . Thus, one can speculate that in the clinical situation, many factors might contribute to inducing severe hypoglycemia in the setting of sulfonylurea treatment, including adjuvant insulin therapy, skipped meals, hypoglycemia unawareness, and/or an impaired counterregulatory response.
In conclusion, treatment with GLIB in nondiabetic rats prevented fatal cardiac arrhythmias during severe hypoglycemia. These findings provide mechanistic insight into the role of K ATP channels in mediating severe hypoglycemia-induced fatal cardiac arrhythmias. In addition, although sulfonylurea treatment increases the risk of severe hypoglycemia, our results have demonstrated that sulfonylureas have a paradoxical marked beneficial effect in mitigating against severe hypoglycemia-induced fatal cardiac arrhythmias.
